RYVU THERAPEUTICS ZY-,40/ PLSELVT00013 /
| 2024-05-21 4:31:29 PM | Chg. +0.080 | Volume | Bid5:36:18 PM | Ask5:36:18 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 12.260EUR | +0.66% | 0 Turnover: 0.000 |
12.000Bid Size: 340 | 13.280Ask Size: 340 | 291.95 mill.EUR | - | - |
GlobeNewswire
2023-12-11
Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Me...
GlobeNewswire
2023-12-07
Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023
GlobeNewswire
2023-11-29
Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
2023-10-23
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Soli...
GlobeNewswire
2023-10-04
Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2...
GlobeNewswire
2023-09-13
Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update
GlobeNewswire
2021-06-25
Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021
